Monocytes mediate Salmonella Typhimurium-induced tumor growth inhibition in a mouse melanoma model

Eur J Immunol. 2021 Dec;51(12):3228-3238. doi: 10.1002/eji.202048913. Epub 2021 Oct 29.

Abstract

The use of bacteria as an alternative cancer therapy has been reinvestigated in recent years. SL7207: an auxotrophic Salmonella enterica serovar Typhimurium aroA mutant with immune-stimulatory potential has proven a promising strain for this purpose. Here, we show that systemic administration of SL7207 induces melanoma tumor growth arrest in vivo, with greater survival of the SL7207-treated group compared to control PBS-treated mice. Administration of SL7207 is accompanied by a change in the immune phenotype of the tumor-infiltrating cells toward pro-inflammatory, with expression of the TH 1 cytokines IFN-γ, TNF-α, and IL-12 significantly increased. Interestingly, Ly6C+ MHCII+ monocytes were recruited to the tumors following SL7207 treatment and were pro-inflammatory. Accordingly, the abrogation of these infiltrating monocytes using clodronate liposomes prevented SL7207-induced tumor growth inhibition. These data demonstrate a previously unappreciated role for infiltrating inflammatory monocytes underlying bacterial-mediated tumor growth inhibition. This information highlights a possible novel role for monocytes in controlling tumor growth, contributing to our understanding of the immune responses required for successful immunotherapy of cancer.

Keywords: Bacterial cancer therapy; Immunotherapy; Monocytes; SL7207.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cytokines / immunology
  • Female
  • Immunotherapy*
  • Melanoma, Experimental* / immunology
  • Melanoma, Experimental* / therapy
  • Mice
  • Monocytes / immunology*
  • Salmonella typhimurium / genetics
  • Salmonella typhimurium / immunology*
  • Th1 Cells / immunology*

Substances

  • Cytokines